

From: Ward-Peralta, Cherie
Sent: Wednesday, November 25, 2015 4:25 PM
To: 'Fernandez, Alexander Maximilian'
Subject: STN 125577 - Information Request - Please respond by December 2, 2015

Follow Up Flag: Follow up
Due By: Wednesday, December 02, 2015 8:00 AM
Flag Status: Flagged

Our Reference: BL 125577/0

Baxalta US Inc.
Attention: Maximilian Fernandez, PhD
Sent by email

Dear Dr. Fernandez:

We are reviewing your December 19, 2014, biologics license application (BLA) for von Willebrand Factor (Recombinant). We determined that the following information is necessary to continue our review:

Vial Label



1. Delete the vial size (i.e., 10 mL) from the description of the vial. Simply use the term “Single-use Vial” instead. There has been a report of medication error due to mistaken of this vial size with the final solution volume.
2. Use consistent terminology for the route of administration if space permits. The carton has “For intravenous administration after reconstitution only.”

The diagram illustrates the layout of a VonVendi von Willebrand Factor (Recombinant) box. The box is divided into several sections:

- Top Flap:** Features a yellow circle on the left and the text "NO COAT" on the right. Dimensions include 100 mm, 100 mm, and 100 mm.
- Front Panel:** Contains the product name "VONVENDI von Willebrand Factor (Recombinant)" and a yellow circle. The text "ACTING PREVENTIVE" is visible on the right side. Dimensions include 100 mm, 100 mm, and 100 mm.
- Bottom Flap:** Features a yellow circle on the left and the text "NO COAT" on the right. Dimensions include 100 mm, 100 mm, and 100 mm.

The diagram is labeled with dimensions and a scale bar. The scale bar indicates 100 mm. The dimensions are given in mm.

3. Delete the vial size (i.e., 10 mL for 650 IU and 30 mL for 1300 IU size) from the description of the vial.
4. Ensure that the storage information is consistent with the information presented in the PI. As currently presented, the carton has 6 months room temperature storage while the PI has up to 12 month room temperature storage.

Please submit your response to this information request as an amendment to this file by December 2, 2015 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is December 19, 2015.

Very Respectfully,

Cherie Ward-Peralta, M.S.

Regulatory Project Manager
Office of Blood Research and Review
Center for Biologics Evaluation and Research
10903 New Hampshire Ave
WO-71- 7328
Silver Spring, MD 20993
Phone: 240-402-8447
Email: cherie.ward-peralta@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."